X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Novartis: Demerger dose takes effect - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Nov 14, 2000

    Novartis: Demerger dose takes effect

    The Novartis stock has been at the receiving end over the past one week. The stock hit a 52 week low of Rs 501 yesterday. The primary reason seems to be the adjustment for the spin off of its agrochemical unit. This is in line with the proposal of its international parent Novartis AG to separate its agrochemical arm. This would then be merged with the agrochemical arm of Astra Zeneca to form a new company Syngenta. In India too the same process is underway.

    The healthcare business (includes the vision care division and the animal health division) is not an asset heavy business since Novartis India outsources most of its production. The top eight brands of the company contribute almost 49% of its formulation sales.

    Product profile
    Major Products Therapeutic area % of pharma
    sales (approx.)
    Voveran Anti–inflammatory & pain 18.0%
    Tegretol Central Nervous System (anti–epileptic) 7.0%
    Rimactazid Anti–TB 4.0%
    PZA–CIBA Anti–TB 4.0%
    Methergine Genito–Urinary System 6.0%
    Regestrone Gynaecological 3.0%
    Otrivin Nasal Decongestant 4.0%
    Macalvit Calcium Supplement 3.0%

    The overall operating margins (excluding other income) of the company, which were around 17% can be expected to increase to around 20% post the hive off of the agrochemical division. Infact, even in the current year first half results, if one were to exclude the pre–tax sales and profits of the agribusiness the pre–tax margins (excluding other income) improve from 9.81% to 11.7% in the current year itself. Also, the company would be able to reduce its working capital requirements since the inventory days and debtors days can almost be halved from the present levels of 70 days and 55 days respectively.

    Consequently, the return on equity would zoom to nearly 35% in FY2001 post hive off. (It stands at 31.6% currently.) Besides, the company has launched five new products over the last two years, all of which are out of the purview of the Drug Price Control Order. This can be expected to improve the margins further.

    New Products introduced over the last two years
    New Products Purpose
    Femara Advanced breast cancer
    Exelon Alzheimer's disease
    Epitril Epilepsy and panic disorders
    PZA–1000 TB
    3FD for treatment of TB

    The improvement in profits, the removal of a seasonal business, the introduction of new products coupled with the almost zero debt status of the company should spell good times for the company. The stock quotes at Rs 501, which implies an earning multiple of 29 times its estimated FY01 earnings.

    Another trigger for the stock could be a sizeable sum which would be received from the grant of development rights at its real estate in Goregaon (a suburb of Mumbai). Last year, the company granted development rights on this real estate and this fetched the company an amount of Rs 66 m. (Novartis’ real estate can fetch it Rs 1.50 bn if it were to give development rights for its entire estate.)

    The only possible dampener to the stock valuations could be the presence of two 100% subsidiaries of the parent, which would be used to launch nutritional products in the future..

     

     

    Equitymaster requests your view! Post a comment on "Novartis: Demerger dose takes effect ". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    NOVARTIS SHARE PRICE


    Aug 22, 2017 (Close)

    TRACK NOVARTIS

    • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    NOVARTIS - TEVA PHARMA COMPARISON

    Compare Company With Charts

    COMPARE NOVARTIS WITH

    MARKET STATS